Haven Private LLC Makes Significant Investment in Novartis AG

During the fourth quarter, Haven Private LLC made a move to strengthen its portfolio by investing in Novartis AG (NYSE:NVS - Free Report). According to the latest filings with the SEC, the firm acquired 2,939 shares of the pharmaceutical giant’s stock, amounting to an investment valued at approximately $286,000.

Investment Trends in Novartis

Several other large investors have also recently made changes to their positions in Novartis. For instance, Human Investing LLC entered a new stake in the company during the fourth quarter worth $25,000. Similarly, Union Bancaire Privee UBP SA invested $27,000 in a new position within the same quarter. Legacy Investment Solutions LLC made a $28,000 investment in the third quarter, while Kestra Investment Management LLC and Brooklyn Investment Group added $47,000 and $55,000 respectively to their positions during the fourth quarter. Collectively, institutional investors currently hold 13.12% of Novartis’s stock.

Novartis Stock Performance

The NVS stock began trading at $113.00 on the last Friday. The stock's 50-day simple moving average stands at $103.67, while the 200-day simple moving average is at $108.02. Financial metrics show a current ratio of 1.04, a quick ratio of 0.84, and a debt-to-equity ratio of 0.48. Over the past year, Novartis AG's stock has reached a low of $92.35 and a high of $120.92, demonstrating a market capitalization of $230.97 billion, alongside a P/E ratio of 19.22 and a P/E/G ratio of 1.70. The stock beta is registered at 0.53.

Quarterly Earnings Review

On January 31st, Novartis reported its quarterly earnings, delivering $1.98 earnings per share for the period, which surpassed analysts' expectations of $1.80 by $0.18. The company showcased a 37.24% return on equity and a net margin of 23.56%. Analysts predict that Novartis AG will achieve an EPS of 8.45 for the current financial year.

Analysts' Ratings on Novartis

Various research analysts have provided insights on NVS shares. Erste Group Bank maintained a "hold" rating for Novartis in a report dated November 19th. Subsequently, Deutsche Bank upgraded the shares from a "hold" to a "buy" on February 4th. StockNews.com further elevated the rating to "strong-buy" on February 8th. Conversely, Barclays reiterated an "underweight" rating, while HSBC downgraded Novartis from a "hold" to a "reduce" on December 4th. Current ratings summary shows three analysts recommending a sell, six suggesting a hold, one advising a buy, and one indicating a strong buy, resulting in an average rating of "Hold" and a price target of $123.38 according to MarketBeat.com data.

Company Overview

Novartis AG is engaged in the research, development, production, and marketing of healthcare products both in Switzerland and globally. The firm offers prescription medications to assist patients and healthcare professionals. Its therapeutic focus encompasses areas such as cardiovascular health, renal and metabolic conditions, immunology, neuroscience, oncology, along with ophthalmology and hematology.

investment, stocks, healthcare